{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:34Z","timestamp":1790837074762,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ebiom.2022.103993","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T05:02:55Z","timestamp":1649739775000},"page":"103993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Tuberculosis vaccines in the era of Covid-19 \u2013 what is taking us so long?"],"prefix":"10.1016","volume":"79","author":[{"given":"Hazel M.","family":"Dockrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.103993_bib0001","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","article-title":"100 years of Mycobacterium bovis bacille Calmette-Gu\u00e9rin","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103993_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.750124","article-title":"Vaccine development against tuberculosis over the last 140 years: failure as part of success","volume":"12","author":"Kaufmann","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ebiom.2022.103993_bib0003","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2022.103993_bib0004","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.103993_bib0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103993_bib0006","unstructured":"TB vaccine pipeline, 2021. https:\/\/www.tbvi.eu\/what-we-do\/pipeline-of-vaccines. Accessed 20 January 2022."},{"key":"10.1016\/j.ebiom.2022.103993_bib0007","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1473-3099(19)30625-5","article-title":"The status of tuberculosis vaccine development","volume":"20","author":"Schrager","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103993_bib0008","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00281-020-00794-0","article-title":"Towards new TB vaccines","volume":"42","author":"Brazier","year":"2020","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ebiom.2022.103993_bib0009","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.3390\/app11199250","article-title":"Tuberculosis vaccines: an update of recent and ongoing clinical trials","volume":"11","author":"Saramago","year":"2021","journal-title":"Appl Sci"},{"key":"10.1016\/j.ebiom.2022.103993_bib0010","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant bacille Calmette-Gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.103993_bib0011","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1016\/j.vaccine.2021.06.049","article-title":"MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG","volume":"39","author":"Mart\u00edn","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2022.103993_bib0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijid.2016.10.018","article-title":"Novel approaches to tuberculosis vaccine development","volume":"56","author":"Kaufmann","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103993_bib0013","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ijid.2020.01.042","article-title":"MDR\/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network","volume":"92S","author":"Migliori","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103993_bib0014","unstructured":"WHO Global TB Report 2021. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2021. Accessed 20 January 2022."},{"key":"10.1016\/j.ebiom.2022.103993_bib0015","doi-asserted-by":"crossref","first-page":"e1132","DOI":"10.1016\/S2214-109X(20)30288-6","article-title":"Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study","volume":"8","author":"Hogan","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ebiom.2022.103993_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0029-2016","article-title":"Pathology of tuberculosis: how the pathology of human tuberculosis informs and directs animal models","volume":"5","author":"Basaraba","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ebiom.2022.103993_bib0017","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.chom.2020.10.003","article-title":"Ultra-low dose aerosol infection of mice with mycobacterium tuberculosis more closely models human tuberculosis","volume":"29","author":"Plumlee","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ebiom.2022.103993_bib0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2017.01.030","article-title":"Experimental animal modelling for TB vaccine development","volume":"56","author":"Cardona","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103993_bib0019","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(02)08353-8","article-title":"BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies","volume":"359","author":"Black","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.103993_bib0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/COH.0b013e3283339309","article-title":"Management of individuals requiring antiretroviral therapy and TB treatment","volume":"5","author":"Cohen","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ebiom.2022.103993_bib0021","doi-asserted-by":"crossref","first-page":"e130090","DOI":"10.1172\/jci.insight.130090","article-title":"Cytomegalovirus infection is a risk factor for tuberculosis disease in infants","volume":"4","author":"M\u00fcller","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2022.103993_bib0022","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tube.2013.12.006","article-title":"Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis","volume":"94","author":"Poyntz","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ebiom.2022.103993_bib0023","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ebiom.2022.103993_bib0024","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.103993_bib0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/ng.590","article-title":"Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved","volume":"42","author":"Comas","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.ebiom.2022.103993_bib0026","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","article-title":"The spectrum of latent tuberculosis: rethinking the biology and intervention strategies","volume":"7","author":"Barry","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ebiom.2022.103993_bib0027","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0437","article-title":"The ongoing challenge of latent tuberculosis","volume":"369","author":"Esmail","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.ebiom.2022.103993_bib0028","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0029","doi-asserted-by":"crossref","first-page":"e00021","DOI":"10.1128\/CMR.00021-18","article-title":"Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection","volume":"31","author":"Drain","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ebiom.2022.103993_bib0030","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41577-018-0025-3","article-title":"Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection","volume":"18","author":"Simmons","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2022.103993_bib0031","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1056\/NEJMc2001468","article-title":"Transmission of 2019-nCoV infection from an asymptomatic contact in Germany","volume":"382","author":"Rothe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0032","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.chom.2018.06.004","article-title":"Mechanisms of M. tuberculosis immune evasion as challenges to TB vaccine design","volume":"24","author":"Ernst","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ebiom.2022.103993_bib0033","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.103993_bib0034","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.201912-2408ED","article-title":"Controlled human infection models: is it really feasible to give people tuberculosis?","volume":"201","author":"McShane","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/rccm.201908-1580OC","article-title":"A human lung challenge model to evaluate the safety and immunogenicity of PPD and live bacillus Calmette-Gu\u00e9rin","volume":"201","author":"Davids","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0036","unstructured":"Clinicaltrials.gov NCT04865237; NCT04864548"},{"key":"10.1016\/j.ebiom.2022.103993_bib0037","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.103993_bib0038","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2022.103993_bib0039","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants","volume":"7","author":"Fletcher","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.103993_bib0040","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1164\/rccm.201003-0334OC","article-title":"Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Gu\u00e9rin vaccination of newborns","volume":"182","author":"Kagina","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0041","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A Functional Role for Antibodies in Tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.103993_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640916","article-title":"Local pulmonary immunological biomarkers in tuberculosis","volume":"12","author":"Morrison","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.103993_bib0043","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4161\/hv.8570","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02A: tolerability and immunogenicity in humans","volume":"5","author":"Von Eschen","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.ebiom.2022.103993_bib0044","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103993_bib0045","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/IAI.72.11.6324-6329.2004","article-title":"RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection","volume":"72","author":"Xue","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.ebiom.2022.103993_bib0046","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/MMBR.00021-14","article-title":"Tuberculosis vaccines and prevention of infection","volume":"78","author":"Hawn","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.ebiom.2022.103993_bib0047","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0048","unstructured":"clinicaltrials.gov NCT03512249"},{"key":"10.1016\/j.ebiom.2022.103993_bib0049","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e9rin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2022.103993_bib0050","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2022.103993_bib0051","unstructured":"Clinicaltrials.gov NCT04351685"},{"key":"10.1016\/j.ebiom.2022.103993_bib0052","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2022.103993_bib0053","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0054","unstructured":"Clinicaltrials.gov NCT04975178"},{"key":"10.1016\/j.ebiom.2022.103993_bib0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.4473","article-title":"Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine","volume":"24","author":"Hansen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0056","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14760584.2019.1692657","article-title":"Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges","volume":"18","author":"Stylianou","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ebiom.2022.103993_bib0057","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41591-018-0319-9","article-title":"Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques","volume":"25","author":"Dijkman","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.103993_bib0058","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tube.2016.09.004","article-title":"Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations","volume":"101","author":"Sharpe","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ebiom.2022.103993_bib0059","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.103993_bib0060","unstructured":"Resolution from United Nations General Assembly high-level meeting on tuberculosis, 26 September 2018, Resolution document A\/RES\/73\/3 accessed 28 February 2022."},{"key":"10.1016\/j.ebiom.2022.103993_bib0061","unstructured":"Tuberculosis Research Funding Trends 2005-2019. Stop TB Partnership and Treatment Action Group. https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2020\/12\/tbrd_2020_final_web.pdf. Accessed 7 March 2022."},{"key":"10.1016\/j.ebiom.2022.103993_bib0062","unstructured":"Collaboration for TB Vaccine Discovery. https:\/\/www.ctvd.org\/Accessed 23 January 2022."},{"key":"10.1016\/j.ebiom.2022.103993_bib0063","unstructured":"TuBerculosis Vaccine Initiative. https:\/\/www.tbvi.eu Accessed 20 January 2022."},{"key":"10.1016\/j.ebiom.2022.103993_bib0064","unstructured":"TB Vaccine Development Pathway. https:\/\/www.tbvacpathway.org Accessed 5 April 2022."}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:15:49Z","timestamp":1762456549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":64,"alternative-id":["S2352396422001773"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103993","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberculosis vaccines in the era of Covid-19 \u2013 what is taking us so long?","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103993"}}